<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28533305</article-id><article-id pub-id-type="pmc">5524070</article-id><article-id pub-id-type="doi">10.1161/JAHA.116.004987</article-id><article-id pub-id-type="publisher-id">JAH32237</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Preventive Cardiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among <styled-content style="fixed-case">HIV</styled-content>&#x02010;Positive Participants in the <styled-content style="fixed-case">START</styled-content> (Strategic Timing of Antiretroviral Treatment) Trial</article-title><alt-title alt-title-type="left-running-head">Baker et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32237-cr-0001" contrib-type="author" corresp="yes"><name><surname>Baker</surname><given-names>Jason V.</given-names></name><degrees>MD, MS</degrees><address><email>baker@umn.edu</email></address><xref ref-type="aff" rid="jah32237-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32237-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32237-cr-0002" contrib-type="author"><name><surname>Sharma</surname><given-names>Shweta</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="jah32237-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32237-cr-0003" contrib-type="author"><name><surname>Achhra</surname><given-names>Amit C.</given-names></name><degrees>MD, PhD, MPH</degrees><xref ref-type="aff" rid="jah32237-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32237-cr-0004" contrib-type="author"><name><surname>Bernardino</surname><given-names>Jose Ignacio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32237-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32237-cr-0005" contrib-type="author"><name><surname>Bogner</surname><given-names>Johannes R.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32237-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jah32237-cr-0006" contrib-type="author"><name><surname>Duprez</surname><given-names>Daniel</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32237-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32237-cr-0007" contrib-type="author"><name><surname>Emery</surname><given-names>Sean</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah32237-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32237-cr-0008" contrib-type="author"><name><surname>Gazzard</surname><given-names>Brian</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32237-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jah32237-cr-0009" contrib-type="author"><name><surname>Gordin</surname><given-names>Jonathan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32237-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="jah32237-cr-0010" contrib-type="author"><name><surname>Grandits</surname><given-names>Greg</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="jah32237-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32237-cr-0011" contrib-type="author"><name><surname>Phillips</surname><given-names>Andrew N.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah32237-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="jah32237-cr-0012" contrib-type="author"><name><surname>Schwarze</surname><given-names>Siegfried</given-names></name><degrees>Dipl Bio</degrees><xref ref-type="aff" rid="jah32237-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="jah32237-cr-0013" contrib-type="author"><name><surname>Soliman</surname><given-names>Elsayed Z.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32237-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="jah32237-cr-0014" contrib-type="author"><name><surname>Spector</surname><given-names>Stephen A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32237-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="jah32237-cr-0015" contrib-type="author"><name><surname>Tambussi</surname><given-names>Giuseppe</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32237-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="jah32237-cr-0016" contrib-type="author"><name><surname>Lundgren</surname><given-names>Jens</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32237-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="jah32237-cr-0017" contrib-type="author"><collab collab-type="authors">the INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group</collab><xref ref-type="author-notes" rid="jah32237-note-1002">
<sup>&#x02020;</sup>
</xref></contrib></contrib-group><aff id="jah32237-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>University of Minnesota</institution>
<named-content content-type="city">Minneapolis</named-content>
<named-content content-type="country-part">MN</named-content>
</aff><aff id="jah32237-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Division of Infectious Diseases</named-content>
<institution>Hennepin County Medical Center</institution>
<named-content content-type="city">Minneapolis</named-content>
<named-content content-type="country-part">MN</named-content>
</aff><aff id="jah32237-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Division of Biostatistics</named-content>
<named-content content-type="organisation-division">School of Public Health</named-content>
<institution>University of Minnesota</institution>
<named-content content-type="city">Minneapolis</named-content>
<named-content content-type="country-part">MN</named-content>
</aff><aff id="jah32237-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Kirby Institute</named-content>
<institution>University of New South Wales</institution>
<named-content content-type="city">Sydney</named-content>
<country country="AU">Australia</country>
</aff><aff id="jah32237-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Hospital La Paz, IdiPAZ</institution>
<named-content content-type="city">Madrid</named-content>
<country country="ES">Spain</country>
</aff><aff id="jah32237-aff-0006">
<label><sup>6</sup></label>
<institution>Division of Infectious Diseases</institution>
<institution>MedIV</institution>
<institution>University Hospital of Munich</institution>
<country country="DE">Germany</country>
</aff><aff id="jah32237-aff-0007">
<label><sup>7</sup></label>
<institution>Chelsea and Westminster Hospital</institution>
<named-content content-type="city">London</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="jah32237-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Division of Cardiology</named-content>
<institution>David Geffen School of Medicine at University of California</institution>
<named-content content-type="city">Los Angeles</named-content>
<named-content content-type="country-part">CA</named-content>
</aff><aff id="jah32237-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">HIV Epidemiology &#x00026; Biostatistics Group</named-content>
<institution>University College London</institution>
<named-content content-type="city">London</named-content>
<country country="GB">United Kingdom</country>
</aff><aff id="jah32237-aff-0010">
<label><sup>10</sup></label>
<institution>European AIDS Treatment Group</institution>
<named-content content-type="city">Berlin</named-content>
<country country="DE">Germany</country>
</aff><aff id="jah32237-aff-0011">
<label><sup>11</sup></label>
<named-content content-type="organisation-division">Epidemiological Cardiology Research Center</named-content>
<institution>Wake Forest School of Medicine</institution>
<named-content content-type="city">Winston Salem</named-content>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="jah32237-aff-0012">
<label><sup>12</sup></label>
<named-content content-type="organisation-division">Division of Pediatric Infectious Diseases</named-content>
<institution>University of California San Diego and Rady Children's Hospital</institution>
<named-content content-type="city">San Diego</named-content>
<named-content content-type="country-part">CA</named-content>
</aff><aff id="jah32237-aff-0013">
<label><sup>13</sup></label>
<institution>San Raffaele Scientific Institute</institution>
<named-content content-type="city">Milano</named-content>
<country country="IT">Italy</country>
</aff><aff id="jah32237-aff-0014">
<label><sup>14</sup></label>
<named-content content-type="organisation-division">CHIP</named-content>
<named-content content-type="organisation-division">Department of Infectious Diseases</named-content>
<institution>Rigshospitalet</institution>
<institution>University of Copenhagen</institution>
<country country="DK">Denmark</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Jason V. Baker, MD, MS, 701 Park Avenue, MC G5, Minneapolis, MN 55417. E&#x02010;mail: <email>baker@umn.edu</email></corresp><fn id="jah32237-note-1002"><label>&#x02020;</label><p>A complete list of the INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group members are given in Appendix&#x000a0;<xref rid="jah32237-sup-0001" ref-type="supplementary-material">S1</xref>.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2017</year></pub-date><volume>6</volume><issue>5</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-5</issue-id><elocation-id>e004987</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e004987.pdf"/><abstract id="jah32237-abs-0001"><sec id="jah32237-sec-0001"><title>Introduction</title><p>
<styled-content style="fixed-case">HIV</styled-content> infection and certain antiretroviral therapy (<styled-content style="fixed-case">ART</styled-content>) medications increase atherosclerotic cardiovascular disease risk, mediated, in part, through traditional cardiovascular disease risk factors.</p></sec><sec id="jah32237-sec-0002"><title>Methods and Results</title><p>We studied cardiovascular disease risk factor changes in the START (Strategic Timing of Antiretroviral Treatment) trial, a randomized study of immediate versus deferred <styled-content style="fixed-case">ART</styled-content> initiation among HIV&#x02010;positive persons with <styled-content style="fixed-case">CD</styled-content>4<sup>+</sup> cell counts &#x0003e;500&#x000a0;cells/mm<sup>3</sup>. Mean change from baseline in risk factors and the incidence of comorbid conditions were compared between groups. The characteristics among 4685 <styled-content style="fixed-case">HIV</styled-content>&#x02010;positive <styled-content style="fixed-case">START</styled-content> trial participants include a median age of 36&#x000a0;years, a CD4 cell count of 651&#x000a0;cells/mm<sup>3</sup>, an HIV viral load of 12&#x000a0;759&#x000a0;copies/mL, a current smoking status of 32%, a median systolic/diastolic blood pressure of 120/76&#x000a0;mm&#x000a0;Hg, and median levels of total cholesterol of 168&#x000a0;mg/dL, low&#x02010;density lipoprotein cholesterol of 102&#x000a0;mg/dL, and high&#x02010;density lipoprotein cholesterol of 41&#x000a0;mg/dL. Mean follow&#x02010;up was 3.0&#x000a0;years. The immediate and deferred <styled-content style="fixed-case">ART</styled-content> groups spent 94% and 28% of follow&#x02010;up time taking <styled-content style="fixed-case">ART</styled-content>, respectively. Compared with patients in the deferral group, patients in the immediate <styled-content style="fixed-case">ART</styled-content> group had increased total cholesterol and low&#x02010;density lipoprotein cholesterol and higher use of lipid&#x02010;lowering therapy (1.2%; 95% <styled-content style="fixed-case">CI</styled-content>, 0.1&#x02013;2.2). Concurrent increases in high&#x02010;density lipoprotein cholesterol with immediate <styled-content style="fixed-case">ART</styled-content> resulted in a 0.1 lower total cholesterol to high&#x02010;density lipoprotein cholesterol ratio (95% <styled-content style="fixed-case">CI</styled-content>, 0.1&#x02013;0.2). Immediate <styled-content style="fixed-case">ART</styled-content> resulted in 2.3% less <styled-content style="fixed-case">BP</styled-content>&#x02010;lowering therapy use (95% <styled-content style="fixed-case">CI</styled-content>, 0.9&#x02013;3.6), but there were no differences in new&#x02010;onset hypertension or diabetes mellitus.</p></sec><sec id="jah32237-sec-0003"><title>Conclusions</title><p>Among HIV&#x02010;positive persons with preserved immunity, immediate <styled-content style="fixed-case">ART</styled-content> led to increases in total cholesterol and low&#x02010;density lipoprotein cholesterol but also concurrent increases in high&#x02010;density lipoprotein cholesterol and decreased use of blood pressure medications. These opposing effects suggest that, in the short term, the net effect of early <styled-content style="fixed-case">ART</styled-content> on traditional cardiovascular disease risk factors may be clinically insignificant."</p></sec><sec id="jah32237-sec-0004"><title>Clinical Trial Registration</title><p>
<styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>00867048.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32237-kwd-0001">antiretroviral therapy</kwd><kwd id="jah32237-kwd-0002">cholesterol</kwd><kwd id="jah32237-kwd-0003"><styled-content style="fixed-case">HIV</styled-content></kwd><kwd id="jah32237-kwd-0004">risk factor</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Lipids and Cholesterol</kwd><kwd>Cardiovascular Disease</kwd><kwd>Risk Factors</kwd></kwd-group><funding-group><award-group><funding-source>National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health</funding-source><award-id>UM1&#x02010;AI068641</award-id><award-id>UMN1&#x02010;AI120197</award-id></award-group></funding-group><funding-group><award-group><funding-source>National Heart, Lung, and Blood Institute</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eunice Kennedy Shriver National Institute of Child Health and Human Development</funding-source></award-group></funding-group><funding-group><award-group><funding-source>National Institute of Mental Health</funding-source></award-group></funding-group><funding-group><award-group><funding-source>National Institute of Neurological Disorders and Stroke</funding-source></award-group></funding-group><funding-group><award-group><funding-source>National Institute of Arthritis and Musculoskeletal and Skin Diseases</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Agence Nationale de Recherches sur le SIDA et les H&#x000e9;patites Virales (France)</funding-source></award-group></funding-group><funding-group><award-group><funding-source>National Health and Medical Research Council (Australia)</funding-source></award-group></funding-group><funding-group><award-group><funding-source>National Research Foundation (Denmark)</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Bundesministerium f&#x000fc;r Bildung und Forschung (Germany)</funding-source></award-group></funding-group><funding-group><award-group><funding-source>European AIDS Treatment Network</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Medical Research Council (United Kingdom)</funding-source></award-group></funding-group><funding-group><award-group><funding-source>National Institute for Health Research</funding-source></award-group></funding-group><funding-group><award-group><funding-source>National Health Service (United Kingdom)</funding-source></award-group></funding-group><funding-group><award-group><funding-source>University of Minnesota</funding-source></award-group></funding-group><funding-group><award-group><funding-source>NIH Cardiovascular Scientist Training Program</funding-source><award-id>T32 HL007895</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="23"/><word-count count="7732"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32237</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.3 mode:remove_FC converted:11.07.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32237-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e004987</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.116.004987">10.1161/JAHA.116.004987</ext-link>.)<pub-id pub-id-type="pmid">28533305</pub-id></mixed-citation>
</p></notes><notes><fn-group id="jah32237-ntgp-0001"><fn id="jah32237-note-1003"><p>Data were presented as a research abstract at the 24th Conference on Retroviruses and Opportunistic Infections, February 22&#x02013;25, 2016, in Boston, MA.</p></fn></fn-group></notes></front><body><sec id="jah32237-sec-0005"><title>Introduction</title><p>HIV&#x02010;positive persons are at increased risk for premature cardiovascular disease (CVD),<xref rid="jah32237-bib-0001" ref-type="ref">1</xref> which is currently a leading cause of morbidity and mortality.<xref rid="jah32237-bib-0002" ref-type="ref">2</xref> Atherosclerotic disease accounts for a substantial proportion of HIV&#x02010;related CVD among contemporary patients. This atherosclerotic disease manifests as excess risk for coronary heart disease (CHD; eg, myocardial infarction)<xref rid="jah32237-bib-0001" ref-type="ref">1</xref> and stroke,<xref rid="jah32237-bib-0003" ref-type="ref">3</xref> and may also contribute to excess risk for heart failure<xref rid="jah32237-bib-0004" ref-type="ref">4</xref> and sudden cardiac death.<xref rid="jah32237-bib-0005" ref-type="ref">5</xref>
</p><p>It is well established that features of both HIV infection and certain antiretroviral medications increase the risk for CVD. Some of this excess CVD risk may be caused by long&#x02010;term systemic inflammation that is mitigated, in part, via antiretroviral therapy (ART)&#x02013;associated viral suppression,<xref rid="jah32237-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32237-bib-0007" ref-type="ref">7</xref>, <xref rid="jah32237-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32237-bib-0009" ref-type="ref">9</xref> whereas some may be caused by exposure to specific antiretrovirals (eg, certain protease inhibitors [PIs] and abacavir)<xref rid="jah32237-bib-0010" ref-type="ref">10</xref> with potential for adverse changes in blood cholesterol, platelet dysfunction, and/or endothelial dysfunction.<xref rid="jah32237-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32237-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32237-bib-0012" ref-type="ref">12</xref>, <xref rid="jah32237-bib-0013" ref-type="ref">13</xref> Despite unique features of HIV disease, traditional risk factors are highly predictive for CVD among HIV&#x02010;positive patients<xref rid="jah32237-bib-0001" ref-type="ref">1</xref>, <xref rid="jah32237-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32237-bib-0014" ref-type="ref">14</xref> and can be adversely affected by HIV infection and ART treatment (eg, dyslipidemia).<xref rid="jah32237-bib-0015" ref-type="ref">15</xref>
</p><p>Given the potential for ART to both increase (via drug toxicity and low&#x02010;density lipoprotein cholesterol [LDL&#x02010;C] increases) and decrease (via viral suppression and reduced inflammation) atherosclerosis, it is important to study this pathophysiology in the context of randomized comparisons. The START (Strategic Timing of Antiretroviral Treatment) trial is a randomized controlled study of immediate initiation of ART (&#x0201c;immediate&#x0201d; group) versus deferral of ART initiation until CD4<sup>+</sup> cell counts decline to &#x0003c;350&#x000a0;cells/mm<sup>3</sup> or clinical symptoms develop (&#x0201c;deferred&#x0201d; group) among participants naive to ART with CD4<sup>+</sup> cell counts &#x0003e;500&#x000a0;cells/mm<sup>3</sup> at entry.<xref rid="jah32237-bib-0016" ref-type="ref">16</xref> The START trial used an ideal design to compare CVD risk factors between ART&#x02010;treated and untreated HIV infection in a controlled fashion among persons at low risk for AIDS. CVD events were a component of the composite end point in the START trial, and participants with a recent CVD event (&#x0003c;6&#x000a0;months from entry) were not eligible. The START trial did not have sufficient power to specifically assess CVD event risk (12 and 14 CVD events in the immediate and deferred groups, respectively).<xref rid="jah32237-bib-0016" ref-type="ref">16</xref> In this study, we characterized the influence of immediate versus deferred ART on CVD risk factor changes and incidence of CVD&#x02010;related comorbidities.</p></sec><sec id="jah32237-sec-0006"><title>Methods</title><sec id="jah32237-sec-0007"><title>Study Design and Data Collection</title><p>The design and primary findings from the START trial have been described.<xref rid="jah32237-bib-0016" ref-type="ref">16</xref>, <xref rid="jah32237-bib-0017" ref-type="ref">17</xref> The START protocol was approved by the human subjects institutional review committee at the University of Minnesota and at all international coordinating centers and participating clinical sites. After informed consent was obtained, data collection occurred at baseline, months 1 and 4, and every 4&#x000a0;months thereafter. Participants were instructed to fast (minimum of 8 hours) for annual blood draws. Laboratory measures were performed using standardized clinical assays at the sites. HIV RNA level, CD4<sup>+</sup> cell count, weight, and blood pressure (BP) were ascertained at every study visit. The BP values used in the analyses were the average of 2 measurements separated by a brief rest. Glucose and serum lipid levels (total cholesterol, high&#x02010;density lipoprotein cholesterol [HDL&#x02010;C], LDL&#x02010;C, and triglycerides) and concomitant medication use were obtained at baseline and annually. At screening, clinicians together with participants prespecified the intended ART regimen a participant would initiate if randomized to the immediate group. This regimen was required to include 2 background nucleoside reverse transcriptase inhibitors plus either a non&#x02010;nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir&#x02010;boosted PI, or an integrase strand transfer inhibitor (INSTI). Defining subgroups by the prespecified ART regimen allowed a randomized comparison between the immediate and deferred groups among those who were designated to start the same antiretroviral medication. Data for this report included visits up to the START trial unblinding date of May 26, 2015.</p></sec><sec id="jah32237-sec-0008"><title>Clinical Comorbidities and Risk Factor Scores</title><p>Dyslipidemia was defined as an LDL&#x02010;C level &#x02265;160&#x000a0;mg/dL or use of lipid&#x02010;lowering therapy. Hypertension was defined as a systolic BP &#x02265;140&#x000a0;mm&#x000a0;Hg, a diastolic BP &#x02265;90&#x000a0;mm&#x000a0;Hg, or use of BP&#x02010;lowering therapy. Diabetes mellitus was defined as a fasting glucose level &#x0003e;126&#x000a0;mg/dL, use of medication for diabetes mellitus, or a clinical diagnosis of diabetes mellitus (adjudicated as confirmed or probable). Body mass index (BMI) was computed using visit&#x02010;specific weight and baseline height. Ten&#x02010;year risk scores were calculated at baseline and updated during follow&#x02010;up for the following<xref rid="jah32237-bib-0018" ref-type="ref">18</xref>, <xref rid="jah32237-bib-0019" ref-type="ref">19</xref>, <xref rid="jah32237-bib-0020" ref-type="ref">20</xref>, <xref rid="jah32237-bib-0021" ref-type="ref">21</xref>: (1) Framingham Risk Score for a CVD or CHD event; (2) D:A:D (Data Collection on Adverse Events of Anti&#x02010;HIV Drugs) risk score for a CVD or CHD event; and (3) the pooled cohort risk assessment for an atherosclerotic CVD event.</p></sec><sec id="jah32237-sec-0009"><title>Statistical Methods</title><p>The mean changes from baseline between the immediate and deferred groups for continuous measures were compared using longitudinal mixed models with random intercepts, including treatment group, visit, and baseline value in the model. The differences between groups for the prevalence of binary measures were compared using generalized estimating equations (binomial regression) with treatment group, visit, and baseline prevalence in the model. Histograms showed that total cholesterol, LDL&#x02010;C, HDL&#x02010;C, and BP were approximately normally distributed and were analyzed untransformed. The proportional hazards assumption was tested using log&#x02010;time as a covariate in the model. Comparisons within subgroups defined by prespecified ART drug or class (efavirenz [EFV], PI, or INSTI) are reported. EFV&#x02010;based ART was included as a subgroup in analyses by ART class, given that EFV represented 95% of the NNRTI use in the START trial. Incidence for binary risk factors was determined in participants without that condition at baseline using a single factor for treatment in Cox regression models. To directly compare treated versus untreated HIV infection we repeated the analyses by excluding immediate group participants who never started ART (n=39) and censoring the deferred group at the time of ART initiation. Analyses were performed using SAS software version 9.3 (SAS Institute Inc) and R software version 3.2.3 (R Foundation for Statistical Computing).</p></sec></sec><sec id="jah32237-sec-0010"><title>Results</title><sec id="jah32237-sec-0011"><title>Participant Characteristics</title><p>A total of 4685 HIV&#x02010;positive individuals from 215 sites in 35 countries were enrolled into the START trial. The median age of participants was 36&#x000a0;years and 27% were female (Table&#x000a0;<xref rid="jah32237-tbl-0001" ref-type="table-wrap">1</xref>).<xref rid="jah32237-bib-0022" ref-type="ref">22</xref> Self&#x02010;reported race/ethnicity reflected global enrollment from the United States (11%), South America and Mexico (25%), Europe, Israel and Australia (35%), Africa (21%), and Asia (8%). The CD4<sup>+</sup> cell count at entry was 651 cells/mm<sup>3</sup>, and the median time since HIV diagnosis was 1&#x000a0;year. Mean (SD) and median [interquartile range] follow&#x02010;up time was 3.0 (1.2) and 2.8 [2.1&#x02013;3.9] years, respectively, with no difference in follow&#x02010;up time between the immediate and deferred groups. Baseline characteristics did not differ between groups (Table&#x000a0;<xref rid="jah32237-tbl-0001" ref-type="table-wrap">1</xref>). In addition to a high smoking prevalence, START trial participants were at low risk for CVD based on the median values for BMI, BP, cholesterol, and CVD/CHD risk scores.</p><table-wrap id="jah32237-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics of Patients in the START Trial (n=4685)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Median [IQR] or % (No.)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Demographics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">36 [29&#x02013;44]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female sex</td><td align="left" rowspan="1" colspan="1">26.8 (1257)</td></tr><tr><td align="left" style="padding-left:10%" colspan="2" rowspan="1">Race</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Asian</td><td align="left" rowspan="1" colspan="1">8.3 (388)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">30.1 (1410)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Latino/Hispanic</td><td align="left" rowspan="1" colspan="1">13.6 (638)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">44.5 (2086)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">3.5 (163)</td></tr><tr><td align="left" colspan="2" rowspan="1">HIV history and laboratory</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Time known to be HIV positive, y</td><td align="left" rowspan="1" colspan="1">1.0 [0.4&#x02013;3.1]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CD4, cells/mm<sup>3</sup>
<xref ref-type="fn" rid="jah32237-note-0005">a</xref>
</td><td align="left" rowspan="1" colspan="1">651 [584&#x02013;765]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nadir CD4, cells/mm<sup>3</sup>
<xref ref-type="fn" rid="jah32237-note-0006">b</xref>
</td><td align="left" rowspan="1" colspan="1">553 [488&#x02013;654]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HIV RNA, copies/mL</td><td align="left" rowspan="1" colspan="1">12&#x000a0;759 [3019&#x02013;43&#x000a0;391]</td></tr><tr><td align="left" colspan="2" rowspan="1">Clinical measures</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">24.6 [22.1&#x02013;27.9]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic BP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">120 [111&#x02013;130]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic BP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">76 [70&#x02013;83]</td></tr><tr><td align="left" colspan="2" rowspan="1">Risk factors</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current smoker</td><td align="left" rowspan="1" colspan="1">31.9 (1496)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">3.3 (156)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior CVD diagnosis<xref ref-type="fn" rid="jah32237-note-0007">c</xref>
</td><td align="left" rowspan="1" colspan="1">0.8 (36)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">19.2 (898)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">BP&#x02010;lowering drugs</td><td align="left" rowspan="1" colspan="1">8.1 (281)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dyslipidemia</td><td align="left" rowspan="1" colspan="1">8.2 (386)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Lipid&#x02010;lowering drugs</td><td align="left" rowspan="1" colspan="1">3.5 (163)</td></tr><tr><td align="left" colspan="2" rowspan="1">Glucose and lipids</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Glucose, mg/dL</td><td align="left" rowspan="1" colspan="1">85 [79&#x02013;92]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol, mg/dL</td><td align="left" rowspan="1" colspan="1">168 [144&#x02013;195]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL&#x02010;C, mg/dL</td><td align="left" rowspan="1" colspan="1">102 [82&#x02013;124]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL&#x02010;C, mg/dL</td><td align="left" rowspan="1" colspan="1">41 [35&#x02013;50]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides, mg/dL</td><td align="left" rowspan="1" colspan="1">97 [71&#x02013;142]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol to HDL&#x02010;C ratio</td><td align="left" rowspan="1" colspan="1">4.0 [3.2&#x02013;5.0]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02013;HDL&#x02010;C, mg/dL</td><td align="left" rowspan="1" colspan="1">124 [102&#x02013;150]</td></tr><tr><td align="left" colspan="2" rowspan="1">10&#x02010;year predicted risk scores</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CVD FRS, %<xref ref-type="fn" rid="jah32237-note-0008">d</xref>
</td><td align="left" rowspan="1" colspan="1">2.3 [0.7&#x02013;6.5]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CHD FRS, %<xref ref-type="fn" rid="jah32237-note-0008">d</xref>
</td><td align="left" rowspan="1" colspan="1">1.9 [0.5&#x02013;5.0]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CVD D:A:D, %<xref ref-type="fn" rid="jah32237-note-0009">e</xref>
</td><td align="left" rowspan="1" colspan="1">1.8 [0.9&#x02013;3.5]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CHD D:A:D, %<xref ref-type="fn" rid="jah32237-note-0009">e</xref>
</td><td align="left" rowspan="1" colspan="1">1.4 [0.7&#x02013;2.9]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pooled cohort ASCVD, %<xref ref-type="fn" rid="jah32237-note-0010">f</xref>
</td><td align="left" rowspan="1" colspan="1">2.2 [1.0&#x02013;4.4]</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lifetime ASCVD risk score, %<xref ref-type="fn" rid="jah32237-note-0011">g</xref>
</td><td align="left" rowspan="1" colspan="1">31.2 [15.6&#x02013;39.6]</td></tr><tr><td align="left" colspan="2" rowspan="1">Prespecified ART regimen</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">EFV</td><td align="left" rowspan="1" colspan="1">75.1 (3516)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PI</td><td align="left" rowspan="1" colspan="1">17.4 (815)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">INSTI</td><td align="left" rowspan="1" colspan="1">3.9 (183)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non&#x02010;EFV NNRTI</td><td align="left" rowspan="1" colspan="1">3.7 (171)</td></tr></tbody></table><table-wrap-foot><fn id="jah32237-note-0004"><p>ART indicates antiretroviral therapy; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CVD, cardiovascular disease; EFV, efavirenz; HDL&#x02010;C, high&#x02010;density lipoprotein cholesterol; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; LDL&#x02010;C, low&#x02010;density lipoprotein cholesterol; NNRTI, non&#x02010;nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; START, Strategic Timing of Antiretroviral Treatment.</p></fn><fn id="jah32237-note-0005"><label>a</label><p>Average of 2 screening values.</p></fn><fn id="jah32237-note-0006"><label>b</label><p>Documented in participant record.</p></fn><fn id="jah32237-note-0007"><label>c</label><p>Diagnosis of any of the following prior to randomization: myocardial infarction, stroke, coronary heart disease requiring drug treatment, coronary revascularization, congestive heart failure, or peripheral arterial disease.</p></fn><fn id="jah32237-note-0008"><label>d</label><p>Framingham Risk Score (FRS) equations in Anderson et&#x000a0;al.<xref rid="jah32237-bib-0018" ref-type="ref">18</xref>
</p></fn><fn id="jah32237-note-0009"><label>e</label><p>Data Collection on Adverse Events of Anti&#x02010;HIV Drugs (D:A:D) score equations in Friis&#x02010;M&#x000f8;ller et&#x000a0;al.<xref rid="jah32237-bib-0019" ref-type="ref">19</xref>
</p></fn><fn id="jah32237-note-0010"><label>f</label><p>Atherosclerotic cardiovascular disease (ASCVD) risk equation&#x000a0;in Goff et&#x000a0;al.<xref rid="jah32237-bib-0020" ref-type="ref">20</xref>
</p></fn><fn id="jah32237-note-0011"><label>g</label><p>Lifetime ASCVD risk score in Berry et&#x000a0;al.<xref rid="jah32237-bib-0022" ref-type="ref">22</xref>
</p></fn></table-wrap-foot></table-wrap><p>The percentage of participants taking ART during follow&#x02010;up is presented in Figure&#x000a0;<xref rid="jah32237-fig-0001" ref-type="fig">1</xref>; 98% of the immediate group and 48% of the deferred group initiated ART, with a median time to initiation of 36&#x000a0;months in the deferred group. The percentage of follow&#x02010;up time spent taking ART was 94% and 28% for the immediate and deferred groups, respectively. The frequency of specific antiretrovirals in the initial ART regimen reflects contemporary clinical practice (Table&#x000a0;<xref rid="jah32237-sup-0001" ref-type="supplementary-material">S1</xref>). Among the 2287 immediate group participants who initiated therapy, ART included tenofovir disoproxil fumarate in 89%, an NNRTI in 77% (73% EFV), a ritonavir&#x02010;boosted PI in 19% (10% atazanavir and 7% darunavir), and an INSTI in 5% (4% raltegravir); corresponding values for the 1134 deferred group participants who initiated therapy included tenofovir disoproxil fumarate in 89%, an NNRTI in 64% (51% EFV), a PI in 22% (11% darunavir), and an INSTI in 14% (8% raltegravir).</p><fig fig-type="Figure" xml:lang="en" id="jah32237-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Antiretroviral therapy (ART) use by treatment group in the <styled-content style="fixed-case">START</styled-content> (Strategic Timing of Antiretroviral Treatment) trial (n=4685). Shown is the percentage of participants taking <styled-content style="fixed-case">ART</styled-content> by follow&#x02010;up month in the immediate and deferred <styled-content style="fixed-case">ART</styled-content> groups. Data were previously reported but the results shown here are truncated at month 48.<xref rid="jah32237-bib-0016" ref-type="ref">16</xref>
</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e004987-g001"/></fig></sec><sec id="jah32237-sec-0012"><title>Changes in Serum Cholesterol Levels and Lipid&#x02010;Lowering Therapy</title><p>Mean changes in lipid levels (Figure&#x000a0;<xref rid="jah32237-fig-0002" ref-type="fig">2</xref>) and the incidence of dyslipidemia (Figure&#x000a0;<xref rid="jah32237-fig-0003" ref-type="fig">3</xref>) are presented for each group. Compared with the ART deferral group, the immediate ART group had 11&#x000a0;mg/dL higher total cholesterol (95% CI, 10&#x02013;13), 6&#x000a0;mg/dL higher LDL&#x02010;C (95% CI, 4&#x02013;7), and 5&#x000a0;mg/dL higher HDL&#x02010;C (95% CI, 4&#x02013;5) levels. The rise in total cholesterol and LDL&#x02010;C in the immediate group was associated with a 1.2% greater use of lipid&#x02010;lowering therapy (95% CI, 0.2&#x02013;2.2) and a higher incidence rate of dyslipidemia (hazard ratio, 1.7; 95% CI, 1.4&#x02013;2.02). Among the 346 participants taking lipid&#x02010;lowering therapy at entry or during follow&#x02010;up, 68% were taking a statin. Increases in HDL&#x02010;C levels resulted in a marginally lower total cholesterol to HDL&#x02010;C ratio in the immediate versus the deferred group (&#x02212;0.1; 95% CI, &#x02212;0.2 to &#x02212;0.1). When HDL &#x0003c;40&#x000a0;mg/dL was included in the criteria for dyslipidemia, 49% (2283) of participants had dyslipidemia at study entry. When including low HDL in the definition, the incidence rate for dyslipidemia was lower in the immediate ART group compared with the deferred ART group (hazard ratio, 0.7; 95% CI, 0.6&#x02013;0.8) (Figure&#x000a0;<xref rid="jah32237-fig-0003" ref-type="fig">3</xref>). Immediate ART also resulted in higher triglyceride (8&#x000a0;mg/dL; 95% CI, 3&#x02013;12) and non&#x02013;HDL&#x02010;C (7&#x000a0;mg/dL; 95% CI, 5&#x02013;8) levels than deferred ART. Participants were fasting for &#x02248;91% of blood draw visits and the findings were similar when analyses were restricted to fasting specimens. In analyses of treated versus untreated HIV infection, the treatment differences in lipid changes from baseline were of higher magnitude but similar.</p><fig fig-type="Figure" xml:lang="en" id="jah32237-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Cardiovascular risk factor changes by treatment group. Shown in the first 3 rows are the unadjusted mean changes from baseline at annual visits for participants in the immediate (I) and deferred (D) antiretroviral therapy (<styled-content style="fixed-case">ART</styled-content>) groups for the following measures: total cholesterol (A), low&#x02010;density lipoprotein cholesterol <styled-content style="fixed-case">(LDL</styled-content>&#x02010;C; B), high&#x02010;density lipoprotein cholesterol (<styled-content style="fixed-case">HDL</styled-content>&#x02010;C; C), total cholesterol to <styled-content style="fixed-case">HDL</styled-content>&#x02010;C ratio (D), systolic blood pressure (<styled-content style="fixed-case">BP</styled-content>; E), and diastolic <styled-content style="fixed-case">BP</styled-content> (F). Presented within (A through F) are the estimated mean differences (with 95% CIs and <italic>P</italic> values) during follow&#x02010;up between the 2 groups (I minus D), adjusting for the baseline value and visit from longitudinal mixed models. Shown in the last row is the unadjusted prevalence (percentage) at baseline and follow&#x02010;up annual visits for participants in both <styled-content style="fixed-case">ART</styled-content> groups for use of <styled-content style="fixed-case">BP</styled-content>&#x02010;lowering drugs (G) and lipid&#x02010;lowering drugs (H). Presented within (G and H) are the overall estimated differences in prevalence during follow&#x02010;up (with 95% CIs and <italic>P</italic> values) between the 2 groups (I minus D), adjusting for the baseline prevalence and visit from generalized estimating equations. Figures are truncated at month 48.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e004987-g002"/></fig><fig fig-type="Figure" xml:lang="en" id="jah32237-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Cumulative incidence of comorbid conditions by treatment group. Shown are Kaplan&#x02013;Meier estimates of the cumulative incidence of participants with dyslipidemia, excluding high&#x02010;density lipoprotein (HDL) in the definition (A), dyslipidemia, including <styled-content style="fixed-case">HDL</styled-content> &#x0003c;40&#x000a0;mg/dL in the definition* (B), hypertension<sup>&#x02020;</sup> (C), and diabetes mellitus (D) during follow&#x02010;up for participants in the immediate (I) and deferred (D) antiretroviral therapy <styled-content style="fixed-case">(ART</styled-content>) groups. Presented within the figures are the estimated hazard ratios (<styled-content style="fixed-case">HRs</styled-content>) for the immediate (I) vs deferred (D) groups (with 95% CIs and <italic>P</italic> values) from Cox proportional hazards regression models. Figures are truncated at month 48. The cumulative incidence plots have jumps annually because measurements were obtained only at annual visits. *A total of 2203 (49%) <styled-content style="fixed-case">START</styled-content> (Strategic Timing of Antiretroviral Treatment) trial participants had dyslipidemia at baseline when including the criteria of <styled-content style="fixed-case">HDL</styled-content> &#x0003c;40&#x000a0;mg/dL. The incidence computation during follow&#x02010;up for this definition is limited to the 2402 participants without baseline dyslipidemia. <sup>&#x02020;</sup>For the incidence computation, an individual was defined as being hypertensive at the first visit when systolic blood pressure (BP) was &#x02265;140&#x000a0;mm&#x000a0;Hg, diastolic <styled-content style="fixed-case">BP</styled-content> was &#x02265;90&#x000a0;mm&#x000a0;Hg, or <styled-content style="fixed-case">BP</styled-content> medication use was reported. In some individuals classified as hypertensive based on <styled-content style="fixed-case">BP</styled-content> alone, the <styled-content style="fixed-case">BP</styled-content> may be lower at subsequent visits. This definition leads to a higher incidence.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-6-e004987-g003"/></fig><p>Table&#x000a0;<xref rid="jah32237-tbl-0002" ref-type="table-wrap">2</xref> presents analyses of subgroups defined by prespecified ART, with comparisons for EFV&#x02010;, PI&#x02010;, and INSTI&#x02010;based ART. These data represent the effect of starting a specific antiretroviral when compared with a group randomized to defer ART but who intended to start the same antiretroviral medication or class. Time spent during follow&#x02010;up taking the prespecified ART varied between 75% and 80% for the immediate group and 15% and 20% for the deferred group. There was a significant interaction between the prespecified ART regimen and the treatment difference for several cholesterol measures. Specifically, participants who prespecified EFV use had a greater difference in both total cholesterol and HDL&#x02010;C level between the immediate and deferred groups, when compared with those who prespecified PI use. Similarly, when compared with those who prespecified an INSTI, the EFV subgroup had greater differences in total cholesterol, LDL&#x02010;C, and HDL&#x02010;C levels between the immediate and deferred groups. Notably, there was no difference in any lipid parameters between immediate and deferred ART among the subgroup that prespecified INSTI use. In analyses of treated versus untreated HIV infection, the magnitude of the treatment differences in lipid changes from baseline was higher for EFV&#x02010; and PI&#x02010;based ART.</p><table-wrap id="jah32237-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Overall Treatment Difference (I&#x02013;D) in Metabolic Parameters by Subgroups Defined by Prespecified ART Regimen at Baseline</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1">Measure</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Prespecified ART</th><th align="left" rowspan="3" valign="top" colspan="1">Interaction <italic>P</italic> Value<xref ref-type="fn" rid="jah32237-note-0014">b</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">EFV (n=3516)</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">PI (n=815)</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">INSTI (n=183)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">I&#x02013;D Mean Difference<xref ref-type="fn" rid="jah32237-note-0013">a</xref> (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">I&#x02013;D Mean Difference<xref ref-type="fn" rid="jah32237-note-0013">a</xref> (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">I&#x02013;D Mean Difference<xref ref-type="fn" rid="jah32237-note-0013">a</xref> (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total cholesterol, mg/dL</td><td align="left" rowspan="1" colspan="1">13.2 (11.5&#x02013;14.9)</td><td align="left" rowspan="1" colspan="1">8.7 (5.2&#x02013;12.1)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.4 (&#x02212;10.1 to 5.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL&#x02010;C, mg/dL</td><td align="left" rowspan="1" colspan="1">6.5 (5.0&#x02013;7.9)</td><td align="left" rowspan="1" colspan="1">3.7 (0.7&#x02013;6.7)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.1 (&#x02212;7.8 to 5.7)</td><td align="left" rowspan="1" colspan="1">0.036</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL&#x02010;C, mg/dL</td><td align="left" rowspan="1" colspan="1">5.8 (5.2&#x02013;6.4)</td><td align="left" rowspan="1" colspan="1">2.2 (0.9&#x02013;3.5)</td><td align="left" rowspan="1" colspan="1">0.4 (&#x02212;2.5 to 3.4)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol to HDL&#x02010;C ratio</td><td align="left" char=" " rowspan="1" colspan="1">&#x02212;0.2 (&#x02212;0.2 to &#x02212;0.1)</td><td align="left" char=" " rowspan="1" colspan="1">&#x02212;0.0 (&#x02212;0.2 to 0.1)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.2 (&#x02212;0.5 to 0.2)</td><td align="left" rowspan="1" colspan="1">0.13</td></tr></tbody></table><table-wrap-foot><fn id="jah32237-note-0012"><p>EFV indicates efavirenz; HDL&#x02010;C, high&#x02010;density lipoprotein cholesterol; INSTI, integrase strand transfer inhibitor; LDL&#x02010;C, low&#x02010;density lipoprotein cholesterol; PI, protease inhibitor.</p></fn><fn id="jah32237-note-0013"><label>a</label><p>Mean differences (immediate [I] minus deferred [D]) during all follow&#x02010;up using longitudinal mixed models adjusting for baseline level and visit.</p></fn><fn id="jah32237-note-0014"><label>b</label><p>2&#x000a0;<italic>df P</italic> value for interaction between treatment group and 3 prespecified antiretroviral therapy (ART) regimens comparing the I&#x02013;D treatment difference among subgroups.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah32237-sec-0013"><title>Changes in BP</title><p>When compared with patients who underwent ART deferral, those who took immediate ART demonstrated no difference in systolic BP, a lower diastolic BP that was not significant (Figure&#x000a0;<xref rid="jah32237-fig-0002" ref-type="fig">2</xref>), and a lower prevalence of BP&#x02010;lowering therapy (&#x02212;2.2%; 95% CI, &#x02212;3.6 to &#x02212;0.93). At entry, 19% of participants had hypertension (per our definition), and when new&#x02010;onset hypertension rates were compared between the immediate and deferred groups, the hazard ratio for reduced incidence of hypertension did not reach significance (0.87; 95% CI, 0.74&#x02013;1.02; [<italic>P</italic>=0.10]) (Figure&#x000a0;<xref rid="jah32237-fig-0003" ref-type="fig">3</xref>). After analyses of treated versus untreated HIV infection, there remained no difference in use of BP&#x02010;lowering therapy or incident hypertension between the groups, whereas diastolic BP was significantly lower in the immediate ART group (&#x02212;0.4; 95% CI, &#x02212;0.1 to &#x02212;0.7 [<italic>P</italic>=0.02]).</p></sec><sec id="jah32237-sec-0014"><title>Changes in Metabolic Parameters</title><p>Patients in the immediate group had a higher mean glucose level of 2&#x000a0;mg/dL (95% CI, 1&#x02013;3) than patients in the deferred group (Figure&#x000a0;<xref rid="jah32237-sup-0001" ref-type="supplementary-material">S1</xref>), but there was no difference in the incidence of type 2 diabetes mellitus (Figure&#x000a0;<xref rid="jah32237-fig-0003" ref-type="fig">3</xref>). In contrast, BMI was significantly lower among patients in the immediate versus deferred groups (&#x02212;0.2&#x000a0;kg/m<sup>2</sup>; 95% CI, &#x02212;0.3 to &#x02212;0.1), although the magnitude of this effect is of unclear clinical significance (Figure&#x000a0;<xref rid="jah32237-sup-0001" ref-type="supplementary-material">S1</xref>). The treatment effect on BMI appeared greatest early after randomization (<italic>P</italic>&#x0003c;0.001 for interaction of treatment group by follow&#x02010;up time). When comparing subgroups defined by prespecified ART regimen, BMI showed a significantly greater decline (with immediate versus deferred ART) among patients in the EFV (&#x02212;0.3&#x000a0;kg/m<sup>2</sup>; 95% CI, &#x02212;0.4 to &#x02212;0.2) versus PI (&#x02212;0.1&#x000a0;kg/m<sup>2</sup>; 95% CI, &#x02212;0.2 to 0.1) subgroups. Finally, there was no evidence of an interaction between prespecified ART regimen and a treatment effect for serum glucose or incident diabetes mellitus.</p></sec><sec id="jah32237-sec-0015"><title>Differences in Risk Factor Profile and Predicted Risk Scores</title><p>We studied the effect of immediate ART on CVD and CHD predicted risk scores. Smoking contributed the most to predicted risk, but rates did not differ between treatment groups during follow&#x02010;up (Figure&#x000a0;<xref rid="jah32237-sup-0001" ref-type="supplementary-material">S1</xref>). The mean difference between groups was not significant for the atherosclerotic CVD pooled cohort 10&#x02010;year risk score (&#x02212;0.1; 95% CI, &#x02212;0.2 to &#x02212;0.1), the Framingham Risk Score 10&#x02010;year CVD (&#x02212;0.1; 95% CI, &#x02212;0.3 to &#x02212;0.0), or the Framingham Risk Score 10&#x02010;year CHD (&#x02212;0.1; 95% CI &#x02212;0.3 to &#x02212;0.0), but was slightly higher in the immediate group for the D:A:D 10&#x02010;year CVD (0.2; 95% CI, 0.1&#x02013;0.3) and CHD (0.1; 95% CI, 0.1&#x02013;0.2) estimates. Differences in the D:A:D scores were caused primarily by the fact that this score considers exposure to certain antiretrovirals (eg, abacavir, lopinavir); there were no differences when censoring participants after initiation of these antiretrovirals. After analyses of patients with treated versus untreated HIV infection, the treatment differences in the Framingham Risk Score estimates were of a similar low magnitude but reached statistical significance.</p></sec></sec><sec id="jah32237-sec-0016"><title>Discussion</title><p>The START trial is the first randomized clinical investigation to study the impact of immediate ART initiation, when compared with deferral, on CVD risk factors among a large global HIV&#x02010;positive cohort with high CD4<sup>+</sup> cell counts. It is in this context that understanding and mitigating risk for CVD becomes a high priority in clinical practice. When compared with ART deferral, ART initiation increased total cholesterol and LDL&#x02010;C levels and use of lipid&#x02010;lowering therapy, but also increased HDL&#x02010;C level and resulted in a decline in total cholesterol to HDL&#x02010;C ratio. Changes in CVD or CHD prediction scores with&#x000a0;immediate versus deferred ART were minimal or nonsignificant.</p><p>A well&#x02010;described consequence of untreated HIV infection is a decline in most serum lipids levels (the primary exception being an elevation in triglycerides), with ART initiation then leading to a compensatory increase in total cholesterol and LDL&#x02010;C levels to a degree that often varies by regimen.<xref rid="jah32237-bib-0015" ref-type="ref">15</xref>, <xref rid="jah32237-bib-0023" ref-type="ref">23</xref>, <xref rid="jah32237-bib-0024" ref-type="ref">24</xref> We present novel randomized data quantifying the absolute effect of ART initiation on serum lipids, when compared with initially untreated HIV disease. Increases in total cholesterol were greatest among the subgroups that prespecified EFV. Prior studies have lacked a comparison group of untreated persons, but have reported greater within&#x02010;participant increases in total cholesterol (mean 19 and 55&#x000a0;mg/dL) and LDL&#x02010;C (mean 4 and 23&#x000a0;mg/dL) levels 1&#x000a0;year after starting NNRTI&#x02010; (eg, EFV) or PI&#x02010;based ART, when compared with the changes reported in the START trial.<xref rid="jah32237-bib-0015" ref-type="ref">15</xref>, <xref rid="jah32237-bib-0025" ref-type="ref">25</xref>, <xref rid="jah32237-bib-0026" ref-type="ref">26</xref> It is unclear whether the greater increases in LDL&#x02010;C level with EFV&#x02010;based ART reflects greater CVD risk, given that increases in HDL&#x02010;C level were also greater with EFV and that epidemiologic data demonstrate that exposure to certain PIs, but not to NNRTIs (eg, EFV), are associated with greater risk for myocardial infarction.<xref rid="jah32237-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32237-bib-0027" ref-type="ref">27</xref>
</p><p>Data from comparative antiretroviral trials have shown the&#x000a0;greatest rises in HDL&#x02010;C level after starting EFV (73% in the&#x000a0;START trial) or tenofovir (89% in the START trial), with the&#x000a0;effect from INSTIs (5% in the START trial) being mixed.<xref rid="jah32237-bib-0025" ref-type="ref">25</xref>, <xref rid="jah32237-bib-0026" ref-type="ref">26</xref>, <xref rid="jah32237-bib-0028" ref-type="ref">28</xref>, <xref rid="jah32237-bib-0029" ref-type="ref">29</xref>, <xref rid="jah32237-bib-0030" ref-type="ref">30</xref>, <xref rid="jah32237-bib-0031" ref-type="ref">31</xref>, <xref rid="jah32237-bib-0032" ref-type="ref">32</xref> Our findings support that ART initiation with EFV&#x02010;based ART led to the greatest increases in HDL&#x02010;C level. Furthermore, the degree of HDL&#x02010;C level increase attributable to initiating EFV&#x02010;based ART was large enough to result in a concurrent decline in the ratio of total cholesterol to HDL&#x02010;C, which was not observed for PI&#x02010; or INSTI&#x02010;based ART. The differential effect on HDL&#x02010;C level by ART regimen and lack of significant INSTI effects on any blood lipids suggests that cholesterol changes may, in part, be mediated via effects other than those related to HIV viral suppression.</p><p>Multiple factors contribute to dyslipidemia among ART&#x02010;treated HIV&#x02010;positive patients, including altered hepatic synthesis, inflammation, oxidative stress, direct drug toxicity (eg, PI binding of the LDL&#x02010;C receptor protein), and possibly genetic factors.<xref rid="jah32237-bib-0023" ref-type="ref">23</xref>, <xref rid="jah32237-bib-0033" ref-type="ref">33</xref>, <xref rid="jah32237-bib-0034" ref-type="ref">34</xref>, <xref rid="jah32237-bib-0035" ref-type="ref">35</xref> The modest degree of ART&#x02010;associated increases in total cholesterol and LDL&#x02010;C levels described in the START trial was surprising, although, as noted, may be caused by the fact that previous estimates cannot isolate the net effect of ART versus no ART. One important caveat to the increase in dyslipidemia with immediate ART in the START trial was that if low HDL level was included as criteria, then dyslipidemia was less with immediate ART. Another important difference between findings from the START trial and most prior ART trials is the health of the study population, raising the question of whether ART&#x02010;related effects on serum lipids may be decreased when initiating treatment earlier in HIV disease. Still, the effect of ART treatment on blood lipid levels in the START trial emphasizes that cholesterol should remain a key target for CVD risk factor modification within this population.</p><p>Although immediate ART initiation did not lead to significant changes in BP or incident hypertension, the use of BP&#x02010;lowering therapy and the prevalence of hypertension were less with immediate ART. Reasons for this discrepancy are unclear, but incident hypertension does not reflect influences on the use of BP&#x02010;lowering therapy among patients with known hypertension at entry. Associations between inflammatory cytokines and vascular stiffness provide some biologic pretense for why suppressing HIV replication may reduce the need for BP therapy.<xref rid="jah32237-bib-0036" ref-type="ref">36</xref>, <xref rid="jah32237-bib-0037" ref-type="ref">37</xref>, <xref rid="jah32237-bib-0038" ref-type="ref">38</xref>, <xref rid="jah32237-bib-0039" ref-type="ref">39</xref> However, if a true ART&#x02010;treatment effect on absolute BP was present but not detected in this study (eg, type 2 error), it is unlikely to be clinically significant.</p><p>ART is well known to be associated with body composition changes, although contemporary ART regimens are less toxic than early&#x02010;era antiretrovirals.<xref rid="jah32237-bib-0040" ref-type="ref">40</xref>, <xref rid="jah32237-bib-0041" ref-type="ref">41</xref>, <xref rid="jah32237-bib-0042" ref-type="ref">42</xref> In the START trial, immediate ART initiation led to a clinically insignificant increase in serum glucose (ie, with no change in incidence of diabetes mellitus), but was also associated with a marginally lower BMI. The BMI findings are counter to prior observations of ART increases in abdominal fat, but, importantly, BMI assessments do not delineate between changes in visceral and subcutaneous fat.<xref rid="jah32237-bib-0041" ref-type="ref">41</xref>, <xref rid="jah32237-bib-0043" ref-type="ref">43</xref> In addition, the relative immune preservation in the START trial may be important in that toxicity from a given antiretroviral medication may be more pronounced among patients with more severe immune depletion. This hypothesis was suggested by notable findings from HOPS (the HIV Outpatient Study), in which starting ART at higher (versus lower) CD4<sup>+</sup> cell counts reduced the incidence of peripheral neuropathy, even when using antiretrovirals well known to cause neuropathy.<xref rid="jah32237-bib-0044" ref-type="ref">44</xref>
</p><p>Ultimately, the net effect of early ART initiation on traditional risk factors appeared to have a clinically insignificant effect on CVD and CHD risk algorithms. While 10&#x02010;year CVD/CHD predicted risk remained low in absolute terms, the estimated lifetime atherosclerotic CVD risk at study entry among this younger population was still &#x0003e;30%,<xref rid="jah32237-bib-0022" ref-type="ref">22</xref> reinforcing that traditional risk factor management remains an important strategy to mitigate the cumulative effects of HIV, ART, and advancing age over time. However, it does remain unclear how well the atherosclerotic CVD lifetime risk estimation reflects true clinical risk in this context as it has not been validated among HIV&#x02010;positive persons.</p><sec id="jah32237-sec-0017"><title>Study Limitations</title><p>These analyses have several limitations. We did not directly assess or characterize other potentially important CVD risk mechanisms (eg, HIV&#x02010;related systemic inflammation) or potential mechanisms of ART toxicity. There was potential for confounding in terms of baseline lipid levels influencing the choice of ART regimen; however, we did not see evidence for this, as the prevalence of prespecified PI (17%) was the same for persons with and without hyperlipidemia at baseline. Also, analyses focused on the INSTI subgroup were limited by small numbers. Finally, we are not able to characterize whether the ART&#x02010;related changes in CVD risk factors will translate to differences in clinical event risk caused by the limited number of events in the START trial, although findings to date have not detected a significant effect of immediate versus deferred ART on risk for CVD events (HR, 0.84; 95% CI, 0.39&#x02013;1.81).<xref rid="jah32237-bib-0016" ref-type="ref">16</xref>
</p></sec></sec><sec id="jah32237-sec-0018"><title>Conclusions</title><p>These data, among a diverse global population of HIV&#x02010;positive persons with high CD4 cell counts, suggest that immediate ART initiation has both positive and negative influences on CVD risk factors. Ultimately, long&#x02010;term follow&#x02010;up in the START trial is needed to determine the net effect of ART treatment initiation for CVD event risk among HIV&#x02010;positive individuals with preserved immunity.</p></sec><sec id="jah32237-sec-0020"><title>Sources of Funding</title><p>The START trial (NCT00867048) is registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>. The START trial is primarily funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under award numbers UM1&#x02010;AI068641 and UMN1&#x02010;AI120197, with additional support from the NIH Clinical Center; National Cancer Institute; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Agence Nationale de Recherches sur le SIDA et les H&#x000e9;patites Virales (France); National Health and Medical Research Council (Australia); National Research Foundation (Denmark); Bundesministerium f&#x000fc;r Bildung und Forschung (Germany); European AIDS Treatment Network; Medical Research Council (United Kingdom); National Institute for Health Research; National Health Service (United Kingdom); and University of Minnesota. Antiretroviral drugs are donated to the central drug repository by AbbVie, Bristol&#x02010;Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, and Merck. Dr Gordin is supported by the NIH Cardiovascular Scientist Training Program under award number T32 HL007895.</p></sec><sec id="jah32237-sec-0021"><title>Disclosures</title><p>The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr Phillips received fees for speaking at 2 meetings sponsored by Gilead Sciences, for consulting from GSK Biologicals, and for attendance at an advisory board membership from AbbVie. The remaining authors declare no relevant financial interests.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jah32237-sup-0001"><caption><p>
<bold>Table&#x000a0;S1.</bold> Distribution (Number and Percentage) of Specific ART Used for the First Regimen and Total Follow&#x02010;Up Time Spent Taking Specific ART (Person&#x02010;Years, Percent of Follow&#x02010;Up)</p><p>
<bold>Figure&#x000a0;S1.</bold> Changes in the prevalence of selected CVD risk factors by treatment group.</p><p>
<bold>Appendix&#x000a0;S1.</bold> The INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.</p></caption><media xlink:href="JAH3-6-e004987-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jah32237-sec-0019"><title>Acknowledgments</title><p>The authors would like to specifically thank the participants in the START trial. See supplemental material for the complete listing of the INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group (also published in <italic>N Engl J Med</italic>. 2015;373:795&#x02013;807).</p></ack><ref-list content-type="cited-references" id="jah32237-bibl-0001"><title>References</title><ref id="jah32237-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32237-cit-0001">
<string-name>
<surname>Freiberg</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Skanderson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lowy</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kraemer</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Butt</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Bidwell Goetz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leaf</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Oursler</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Rimland</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rodriguez Barradas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gibert</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>McGinnis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Crothers</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sico</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Crane</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Warner</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gottlieb</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gottdiener</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tracy</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Budoff</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Watson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Armah</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Doebler</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bryant</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Justice</surname>
<given-names>AC</given-names>
</string-name>. <article-title>HIV infection and the risk of acute myocardial infarction</article-title>. <source>JAMA Intern Med</source>. <year>2013</year>;<volume>173</volume>:<fpage>614</fpage>&#x02013;<lpage>622</lpage>.<pub-id pub-id-type="pmid">23459863</pub-id></mixed-citation></ref><ref id="jah32237-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32237-cit-0002">
<string-name>
<surname>Miller</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Bormann</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Erlandson</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Huppler Hullsiek</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Justice</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Neuhaus</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Paredes</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Petoumenos</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wentworth</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Winston</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wolfson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Neaton</surname>
<given-names>JD</given-names>
</string-name>; <collab collab-type="authors">INSIGHT SMART Study Group; ESPRIT Study Group</collab>
. <article-title>Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>:<fpage>e95061</fpage>.<pub-id pub-id-type="pmid">24728071</pub-id></mixed-citation></ref><ref id="jah32237-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32237-cit-0003">
<string-name>
<surname>Sico</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>So&#x02010;Armah</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Justice</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Hylek</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Skanderson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McGinnis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Kraemer</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Rimland</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bidwell Goetz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Butt</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Rodriguez&#x02010;Barradas</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Gibert</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Leaf</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Samet</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kazis</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bryant</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Freiberg</surname>
<given-names>MS</given-names>
</string-name>; <collab collab-type="authors">Veterans Aging Cohort Study</collab>
. <article-title>HIV status and the risk of ischemic stroke among men</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>84</volume>:<fpage>1933</fpage>&#x02013;<lpage>1940</lpage>.<pub-id pub-id-type="pmid">25862803</pub-id></mixed-citation></ref><ref id="jah32237-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32237-cit-0004">
<string-name>
<surname>Butt</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Goetz</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Leaf</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rimland</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gibert</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Oursler</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Rodriguez&#x02010;Barradas</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kazis</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Gottlieb</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Justice</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Freiberg</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease</article-title>. <source>Arch Intern Med</source>. <year>2011</year>;<volume>171</volume>:<fpage>737</fpage>&#x02013;<lpage>743</lpage>.<pub-id pub-id-type="pmid">21518940</pub-id></mixed-citation></ref><ref id="jah32237-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32237-cit-0005">
<string-name>
<surname>Tseng</surname>
<given-names>ZH</given-names>
</string-name>, <string-name>
<surname>Secemsky</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Dowdy</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Vittinghoff</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Moyers</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Havlir</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Hsue</surname>
<given-names>PY</given-names>
</string-name>. <article-title>Sudden cardiac death in patients with human immunodeficiency virus infection</article-title>. <source>J Am Coll Cardiol</source>. <year>2012</year>;<volume>59</volume>:<fpage>1891</fpage>&#x02013;<lpage>1896</lpage>.<pub-id pub-id-type="pmid">22595409</pub-id></mixed-citation></ref><ref id="jah32237-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32237-cit-0006">
<string-name>
<surname>Duprez</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Neuhaus</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Tracy</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Belloso</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>De Wit</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Drummond</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lane</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Ledergerber</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lundgren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nixon</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Paton</surname>
<given-names>NI</given-names>
</string-name>, <string-name>
<surname>Prineas</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Neaton</surname>
<given-names>JD</given-names>
</string-name>; <collab collab-type="authors">INSIGHT SMART Study Group</collab>
. <article-title>Inflammation, coagulation and cardiovascular disease in HIV&#x02010;infected individuals</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e44454</fpage>.<pub-id pub-id-type="pmid">22970224</pub-id></mixed-citation></ref><ref id="jah32237-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32237-cit-0007">
<string-name>
<surname>Triant</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Regan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sax</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Meigs</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Grinspoon</surname>
<given-names>SK</given-names>
</string-name>. <article-title>Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2010</year>;<volume>55</volume>:<fpage>615</fpage>&#x02013;<lpage>619</lpage>.<pub-id pub-id-type="pmid">20827215</pub-id></mixed-citation></ref><ref id="jah32237-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32237-cit-0008">
<collab collab-type="authors">Strategies for Management of Antiretroviral Therapy (SMART) Study Group</collab>
, <string-name>
<surname>El&#x02010;Sadr</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Lundgren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Neaton</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Gordin</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Abrams</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Arduino</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Babiker</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Burman</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Clumeck</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Cohn</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Darbyshire</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Emery</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fatkenheuer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gazzard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Grund</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hoy</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Klingman</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Losso</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Markowitz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Neuhaus</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rappoport</surname>
<given-names>C</given-names>
</string-name>. <article-title>CD4+ count&#x02010;guided interruption of antiretroviral treatment</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>:<fpage>2283</fpage>&#x02013;<lpage>2296</lpage>.<pub-id pub-id-type="pmid">17135583</pub-id></mixed-citation></ref><ref id="jah32237-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32237-cit-0009">
<string-name>
<surname>Baker</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Neuhaus</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Duprez</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Tracy</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Belloso</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>De Wit</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Drummond</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lane</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Ledergerber</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lundgren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nixon</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Paton</surname>
<given-names>NI</given-names>
</string-name>, <string-name>
<surname>Neaton</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2011</year>;<volume>56</volume>:<fpage>36</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">20930640</pub-id></mixed-citation></ref><ref id="jah32237-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32237-cit-0010">
<string-name>
<surname>Friis&#x02010;Moller</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Reiss</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sabin</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Weber</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Monforte</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>El&#x02010;Sadr</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Thiebaut</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>De Wit</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kirk</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Fontas</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Law</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lundgren</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Class of antiretroviral drugs and the risk of myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>356</volume>:<fpage>1723</fpage>&#x02013;<lpage>1735</lpage>.<pub-id pub-id-type="pmid">17460226</pub-id></mixed-citation></ref><ref id="jah32237-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah32237-cit-0011">
<string-name>
<surname>Stein</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Bellehumeur</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>McBride</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Wiebe</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Otvos</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Sosman</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Use of human immunodeficiency virus&#x02010;1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>:<fpage>257</fpage>&#x02013;<lpage>262</lpage>.<pub-id pub-id-type="pmid">11457741</pub-id></mixed-citation></ref><ref id="jah32237-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32237-cit-0012">
<string-name>
<surname>Shankar</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Dube</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Gorski</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Klaunig</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Steinberg</surname>
<given-names>HO</given-names>
</string-name>. <article-title>Indinavir impairs endothelial function in healthy HIV&#x02010;negative men</article-title>. <source>Am Heart J</source>. <year>2005</year>;<volume>150</volume>:<fpage>933</fpage>.</mixed-citation></ref><ref id="jah32237-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32237-cit-0013">
<string-name>
<surname>Satchell</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>O'Halloran</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Cotter</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Peace</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>O'Connor</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Tedesco</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Feeney</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Lambert</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Sheehan</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Kenny</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mallon</surname>
<given-names>PW</given-names>
</string-name>. <article-title>Increased platelet reactivity in HIV&#x02010;1&#x02010;infected patients receiving abacavir&#x02010;containing antiretroviral therapy</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>204</volume>:<fpage>1202</fpage>&#x02013;<lpage>1210</lpage>.<pub-id pub-id-type="pmid">21917893</pub-id></mixed-citation></ref><ref id="jah32237-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32237-cit-0014">
<string-name>
<surname>Triant</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hadigan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Grinspoon</surname>
<given-names>SK</given-names>
</string-name>. <article-title>Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>:<fpage>2506</fpage>&#x02013;<lpage>2512</lpage>.<pub-id pub-id-type="pmid">17456578</pub-id></mixed-citation></ref><ref id="jah32237-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32237-cit-0015">
<string-name>
<surname>Riddler</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Smit</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chmiel</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Dobs</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Palella</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Visscher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kingsley</surname>
<given-names>LA</given-names>
</string-name>. <article-title>Impact of HIV infection and HAART on serum lipids in men</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>289</volume>:<fpage>2978</fpage>&#x02013;<lpage>2982</lpage>.<pub-id pub-id-type="pmid">12799406</pub-id></mixed-citation></ref><ref id="jah32237-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah32237-cit-0016">
<collab collab-type="authors">INSIGHT Start Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, F&#x000e4;tkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD</collab>
. <article-title>Initiation of antiretroviral therapy in early asymptomatic HIV infection</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>795</fpage>&#x02013;<lpage>807</lpage>.<pub-id pub-id-type="pmid">26192873</pub-id></mixed-citation></ref><ref id="jah32237-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah32237-cit-0017">
<string-name>
<surname>Babiker</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Emery</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fatkenheuer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gordin</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Grund</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lundgren</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Neaton</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Pett</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Touloumi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Vjechaj</surname>
<given-names>MJ</given-names>
</string-name>; <collab collab-type="authors">INSIGHT START Study Group</collab>
. <article-title>Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study</article-title>. <source>Clin Trials</source>. <year>2013</year>;<volume>10</volume>:<fpage>S5</fpage>&#x02013;<lpage>S36</lpage>.<pub-id pub-id-type="pmid">22547421</pub-id></mixed-citation></ref><ref id="jah32237-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah32237-cit-0018">
<string-name>
<surname>Anderson</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Odell</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Kannel</surname>
<given-names>WB</given-names>
</string-name>. <article-title>Cardiovascular disease risk profiles</article-title>. <source>Am Heart J</source>. <year>1991</year>;<volume>121</volume>:<fpage>293</fpage>&#x02013;<lpage>298</lpage>.<pub-id pub-id-type="pmid">1985385</pub-id></mixed-citation></ref><ref id="jah32237-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah32237-cit-0019">
<string-name>
<surname>Friis&#x02010;M&#x000f8;ller</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Thiebaut</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Reiss</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Weber</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Monforte</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>De Wit</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>El&#x02010;Sadr</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Fontas</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Worm</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kirk</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sabin</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Lundgren</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Law</surname>
<given-names>MG</given-names>
</string-name>. <article-title>Predicting the risk of cardiovascular disease in HIV&#x02010;infected patients: the data collection on adverse effects of anti&#x02010;HIV drugs study</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source>. <year>2010</year>;<volume>17</volume>:<fpage>491</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">20543702</pub-id></mixed-citation></ref><ref id="jah32237-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah32237-cit-0020">
<string-name>
<surname>Goff</surname>
<given-names>DC</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Lloyd&#x02010;Jones</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Coady</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>D'Agostino</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Gibbons</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Greenland</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lackland</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>O'Donnell</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Shero</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>SC</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Sorlie</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Stone</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Nevo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wnek</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Halperin</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Albert</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Bozkurt</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Brindis</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Curtis</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>DeMets</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hochman</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Kovacs</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Pressler</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Sellke</surname>
<given-names>FW</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>SC</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Tomaselli</surname>
<given-names>GF</given-names>
</string-name>. <article-title>2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>129</volume>:<fpage>S49</fpage>&#x02013;<lpage>S73</lpage>.<pub-id pub-id-type="pmid">24222018</pub-id></mixed-citation></ref><ref id="jah32237-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah32237-cit-0021">
<string-name>
<surname>Stamler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Stamler</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Neaton</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Wentworth</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Daviglus</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Garside</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dyer</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Greenland</surname>
<given-names>P</given-names>
</string-name>. <article-title>Low risk&#x02010;factor profile and long&#x02010;term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle&#x02010;aged men and women</article-title>. <source>JAMA</source>. <year>1999</year>;<volume>282</volume>:<fpage>2012</fpage>&#x02013;<lpage>2018</lpage>.<pub-id pub-id-type="pmid">10591383</pub-id></mixed-citation></ref><ref id="jah32237-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah32237-cit-0022">
<string-name>
<surname>Berry</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Dyer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cai</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Garside</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Ning</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Greenland</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Van Horn</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tracy</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Lloyd&#x02010;Jones</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Lifetime risks of cardiovascular disease</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>:<fpage>321</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">22276822</pub-id></mixed-citation></ref><ref id="jah32237-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah32237-cit-0023">
<string-name>
<surname>Kelesidis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Currier</surname>
<given-names>JS</given-names>
</string-name>. <article-title>Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection</article-title>. <source>Endocrinol Metab Clin North Am</source>. <year>2014</year>;<volume>43</volume>:<fpage>665</fpage>&#x02013;<lpage>684</lpage>.<pub-id pub-id-type="pmid">25169560</pub-id></mixed-citation></ref><ref id="jah32237-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah32237-cit-0024">
<string-name>
<surname>Grunfeld</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Doerrler</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Shigenaga</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Feingold</surname>
<given-names>KR</given-names>
</string-name>. <article-title>Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1992</year>;<volume>74</volume>:<fpage>1045</fpage>&#x02013;<lpage>1052</lpage>.<pub-id pub-id-type="pmid">1373735</pub-id></mixed-citation></ref><ref id="jah32237-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah32237-cit-0025">
<string-name>
<surname>Hill</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sawyer</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Gazzard</surname>
<given-names>B</given-names>
</string-name>. <article-title>Effects of first&#x02010;line use of nucleoside analogues, efavirenz, and ritonavir&#x02010;boosted protease inhibitors on lipid levels</article-title>. <source>HIV Clin Trials</source>. <year>2009</year>;<volume>10</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">19362991</pub-id></mixed-citation></ref><ref id="jah32237-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah32237-cit-0026">
<string-name>
<surname>Quercia</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Martin&#x02010;Carpenter</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zala</surname>
<given-names>C</given-names>
</string-name>. <article-title>Comparative changes of lipid levels in treatment&#x02010;naive, HIV&#x02010;1&#x02010;infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir&#x02010;boosted darunavir&#x02010;based regimens over 48&#x000a0;weeks</article-title>. <source>Clin Drug Invest</source>. <year>2015</year>;<volume>35</volume>:<fpage>211</fpage>&#x02013;<lpage>219</lpage>.</mixed-citation></ref><ref id="jah32237-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah32237-cit-0027">
<string-name>
<surname>Rosenblatt</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Farr</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Nkhoma</surname>
<given-names>ET</given-names>
</string-name>. <article-title>Risk of cardiovascular events among patients initiating efavirenz&#x02010;containing versus efavirenz&#x02010;free antiretroviral regimens</article-title>. <source>Open Forum Infect Dis</source>. <year>2016</year>;<volume>3</volume>:<fpage>ofw061</fpage>.<pub-id pub-id-type="pmid">27186585</pub-id></mixed-citation></ref><ref id="jah32237-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah32237-cit-0028">
<string-name>
<surname>Daar</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Tierney</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fischl</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Sax</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Mollan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Budhathoki</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Godfrey</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jahed</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Myers</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Katzenstein</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Farajallah</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rooney</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Pappa</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Woodward</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Patterson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bolivar</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Benson</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Collier</surname>
<given-names>AC</given-names>
</string-name>; <collab collab-type="authors">AIDS Clinical Trials Group Study A5202 Team</collab>
. <article-title>Atazanavir plus ritonavir or efavirenz as part of a 3&#x02010;drug regimen for initial treatment of HIV&#x02010;1</article-title>. <source>Ann Intern Med</source>. <year>2011</year>;<volume>154</volume>:<fpage>445</fpage>&#x02013;<lpage>456</lpage>.<pub-id pub-id-type="pmid">21320923</pub-id></mixed-citation></ref><ref id="jah32237-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah32237-cit-0029">
<string-name>
<surname>DeJesus</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rockstroh</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Molina</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Gathe</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ramanathan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Yale</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Szwarcberg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Kearney</surname>
<given-names>BP</given-names>
</string-name>; <collab collab-type="authors">Team GSS</collab>
. <article-title>Co&#x02010;formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir&#x02010;boosted atazanavir plus co&#x02010;formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV&#x02010;1 infection: a randomised, double&#x02010;blind, phase 3, non&#x02010;inferiority trial</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>379</volume>:<fpage>2429</fpage>&#x02013;<lpage>2438</lpage>.<pub-id pub-id-type="pmid">22748590</pub-id></mixed-citation></ref><ref id="jah32237-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah32237-cit-0030">
<string-name>
<surname>Ofotokun</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Na</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Landovitz</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Ribaudo</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>McComsey</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Godfrey</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Aweeka</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Cohn</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Sagar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kuritzkes</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Patterson</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Para</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Leavitt</surname>
<given-names>RY</given-names>
</string-name>, <string-name>
<surname>Villasis&#x02010;Keever</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baugh</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Lennox</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Currier</surname>
<given-names>JS</given-names>
</string-name>; <collab collab-type="authors">AIDS Clinical Trials Group (ACTG) A5257 Team</collab>
. <article-title>Comparison of the metabolic effects of ritonavir&#x02010;boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257</article-title>. <source>Clin Infect Dis</source>. <year>2015</year>;<volume>60</volume>:<fpage>1842</fpage>&#x02013;<lpage>1851</lpage>.<pub-id pub-id-type="pmid">25767256</pub-id></mixed-citation></ref><ref id="jah32237-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah32237-cit-0031">
<string-name>
<surname>Wohl</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gallant</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Mills</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sax</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Dejesus</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Zolopa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Plummer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Rhee</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Szwarcberg</surname>
<given-names>J</given-names>
</string-name>; <collab collab-type="authors">GS&#x02010;US&#x02010;236&#x02010;0102 Study Team</collab>
. <article-title>A randomized, double&#x02010;blind comparison of single&#x02010;tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single&#x02010;tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV&#x02010;1 infection: analysis of week 144 results</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2014</year>;<volume>65</volume>:<fpage>e118</fpage>&#x02013;<lpage>e120</lpage>.<pub-id pub-id-type="pmid">24256630</pub-id></mixed-citation></ref><ref id="jah32237-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah32237-cit-0032">
<string-name>
<surname>Rockstroh</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>DeJesus</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lennox</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Yazdanpanah</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Saag</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Wan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rodgers</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>DiNubile</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>BY</given-names>
</string-name>, <string-name>
<surname>Teppler</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Leavitt</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sklar</surname>
<given-names>P</given-names>
</string-name>; <collab collab-type="authors">STARTMRK Investigators</collab>
. <article-title>Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment&#x02010;naive HIV&#x02010;1&#x02010;infected patients: final 5&#x02010;year results from STARTMRK</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2013</year>;<volume>63</volume>:<fpage>77</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">23412015</pub-id></mixed-citation></ref><ref id="jah32237-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah32237-cit-0033">
<string-name>
<surname>Mujawar</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Rose</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Morrow</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Pushkarsky</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dubrovsky</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Mukhamedova</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Dart</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Orenstein</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Bobryshev</surname>
<given-names>YV</given-names>
</string-name>, <string-name>
<surname>Bukrinsky</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sviridov</surname>
<given-names>D</given-names>
</string-name>. <article-title>Human immunodeficiency virus impairs reverse cholesterol transport from macrophages</article-title>. <source>PLoS Biol</source>. <year>2006</year>;<volume>4</volume>:<fpage>e365</fpage>.<pub-id pub-id-type="pmid">17076584</pub-id></mixed-citation></ref><ref id="jah32237-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah32237-cit-0034">
<string-name>
<surname>Feingold</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Grunfeld</surname>
<given-names>C</given-names>
</string-name>. <article-title>The acute phase response inhibits reverse cholesterol transport</article-title>. <source>J Lipid Res</source>. <year>2010</year>;<volume>51</volume>:<fpage>682</fpage>&#x02013;<lpage>684</lpage>.<pub-id pub-id-type="pmid">20071695</pub-id></mixed-citation></ref><ref id="jah32237-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah32237-cit-0035">
<string-name>
<surname>Stein</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Komarow</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cotter</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Currier</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Dube</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Fichtenbaum</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Gerschenson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Squires</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Parker</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Torriani</surname>
<given-names>FJ</given-names>
</string-name>. <article-title>Lipoprotein changes in HIV&#x02010;infected antiretroviral&#x02010;naive individuals after starting antiretroviral therapy: ACTG Study A5152s stein: lipoprotein changes on antiretroviral therapy</article-title>. <source>J Clin Lipidol</source>. <year>2008</year>;<volume>2</volume>:<fpage>464</fpage>&#x02013;<lpage>471</lpage>.<pub-id pub-id-type="pmid">19956354</pub-id></mixed-citation></ref><ref id="jah32237-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jah32237-cit-0036">
<string-name>
<surname>Mahmud</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Feely</surname>
<given-names>J</given-names>
</string-name>. <article-title>Arterial stiffness is related to systemic inflammation in essential hypertension</article-title>. <source>Hypertension</source>. <year>2005</year>;<volume>46</volume>:<fpage>1118</fpage>&#x02013;<lpage>1122</lpage>.<pub-id pub-id-type="pmid">16216991</pub-id></mixed-citation></ref><ref id="jah32237-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jah32237-cit-0037">
<string-name>
<surname>Schnabel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Larson</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Dupuis</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lunetta</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Lipinska</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Meigs</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Yin</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Rong</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vita</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Newton&#x02010;Cheh</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Keaney</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Vasan</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection</article-title>. <source>Hypertension</source>. <year>2008</year>;<volume>51</volume>:<fpage>1651</fpage>&#x02013;<lpage>1657</lpage>.<pub-id pub-id-type="pmid">18426996</pub-id></mixed-citation></ref><ref id="jah32237-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jah32237-cit-0038">
<string-name>
<surname>Bautista</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Vera</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Arenas</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Gamarra</surname>
<given-names>G</given-names>
</string-name>. <article-title>Independent association between inflammatory markers (C&#x02010;reactive protein, interleukin&#x02010;6, and TNF&#x02010;alpha) and essential hypertension</article-title>. <source>J Hum Hypertens</source>. <year>2005</year>;<volume>19</volume>:<fpage>149</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">15361891</pub-id></mixed-citation></ref><ref id="jah32237-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jah32237-cit-0039">
<string-name>
<surname>Chae</surname>
<given-names>CU</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>RT</given-names>
</string-name>, <string-name>
<surname>Rifai</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Blood pressure and inflammation in apparently healthy men</article-title>. <source>Hypertension</source>. <year>2001</year>;<volume>38</volume>:<fpage>399</fpage>&#x02013;<lpage>403</lpage>.<pub-id pub-id-type="pmid">11566912</pub-id></mixed-citation></ref><ref id="jah32237-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jah32237-cit-0040">
<string-name>
<surname>Grinspoon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Carr</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cardiovascular risk and body&#x02010;fat abnormalities in HIV&#x02010;infected adults</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>48</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">15635112</pub-id></mixed-citation></ref><ref id="jah32237-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jah32237-cit-0041">
<string-name>
<surname>McComsey</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Moser</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Currier</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ribaudo</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Paczuski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dube</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Kelesidis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rothenberg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>TT</given-names>
</string-name>. <article-title>Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s</article-title>. <source>Clin Infect Dis</source>. <year>2016</year>;<volume>62</volume>:<fpage>853</fpage>&#x02013;<lpage>862</lpage>.<pub-id pub-id-type="pmid">26797215</pub-id></mixed-citation></ref><ref id="jah32237-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jah32237-cit-0042">
<string-name>
<surname>McComsey</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Kitch</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sax</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Tebas</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tierney</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jahed</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Myers</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Melbourne</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ha</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Daar</surname>
<given-names>ES</given-names>
</string-name>. <article-title>Peripheral and central fat changes in subjects randomized to abacavir&#x02010;lamivudine or tenofovir&#x02010;emtricitabine with atazanavir&#x02010;ritonavir or efavirenz: ACTG Study A5224s</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>53</volume>:<fpage>185</fpage>&#x02013;<lpage>196</lpage>.<pub-id pub-id-type="pmid">21690627</pub-id></mixed-citation></ref><ref id="jah32237-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jah32237-cit-0043">
<string-name>
<surname>Joy</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Keogh</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Hadigan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dolan</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Fitch</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Liebau</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Johnsen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Grinspoon</surname>
<given-names>SK</given-names>
</string-name>. <article-title>Relation of body composition to body mass index in HIV&#x02010;infected patients with metabolic abnormalities</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2008</year>;<volume>47</volume>:<fpage>174</fpage>&#x02013;<lpage>184</lpage>.<pub-id pub-id-type="pmid">17971710</pub-id></mixed-citation></ref><ref id="jah32237-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jah32237-cit-0044">
<string-name>
<surname>Lichtenstein</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Armon</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Buchacz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Chmiel</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Moorman</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Holmberg</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Brooks</surname>
<given-names>JT</given-names>
</string-name>; <collab collab-type="authors">HIV Outpatient Study Investigators</collab>
. <article-title>Initiation of antiretroviral therapy at CD4 cell counts &#x0003e;/=350 cells/mm<sup>3</sup> does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2008</year>;<volume>47</volume>:<fpage>27</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">17971714</pub-id></mixed-citation></ref></ref-list></back></article>